1. World Health Organization (2011) Global tuberculosis control: WHO report 2011. Geneva: World Health Organization.
2. ObermeyerZ, Abbott-KlafterJ, MurrayCJ (2008) Has the DOTS strategy improved case finding or treatment success? An empirical assessment. PLoS ONE 3: e1721 doi:10.1371/journal.pone.0001721.
3. DenkingerCM, PaiM (2011) Point-of-care tuberculosis diagnosis: are we there yet? Lancet Infect Dis 12: 169–170.
4. CorbettEL, WattCJ, WalkerN, MaherD, WilliamsBG, et al. (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163: 1009–1021.
5. ElliottAM, HalwiindiB, HayesRJ, LuoN, TemboG, et al. (1993) The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia. J Trop Med Hyg 96: 1–11.
6. GetahunH, HarringtonM, O'BrienR, NunnP (2007) Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 369: 2042–2049.
7. Acuna-VillaordunaC, VassallA, HenostrozaG, SeasC, GuerraH, et al. (2008) Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries. Clin Infect Dis 47: 487–495.
8. Van DeunA, MartinA, PalominoJC (2010) Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection. Int J Tuberc Lung Dis 14: 131–140.
9. ParsonsLM, SomoskoviA, GutierrezC, LeeE, ParamasivanCN, et al. (2011) Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin Microbiol Rev 24: 314–350.
10. Tuberculosis Division (2005) Tuberculosis bacteriology—priorities and indications in high prevalence countries: position of the technical staff of the Tuberculosis Division of the International Union Against Tuberculosis and Lung Disease. Int J Tuberc Lung Dis 9: 355–361.
11. FarmerP, BayonaJ, BecerraM, FurinJ, HenryC, et al. (1998) The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis 2: 869–876.
12. MeintjesG, SchoemanH, MorroniC, WilsonD, MaartensG (2008) Patient and provider delay in tuberculosis suspects from communities with a high HIV prevalence in South Africa: a cross-sectional study. BMC Infect Dis 8: 72.
13. Van RieA, EnarsonD (2006) XDR tuberculosis: an indicator of public-health negligence. Lancet 368: 1554–1556.
14. BoehmeCC, NabetaP, HillemannD, NicolMP, ShenaiS, et al. (2010) Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363: 1005–1015.
15. BoehmeCC, NicolMP, NabetaP, MichaelJS, GotuzzoE, et al. (2011) Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377: 1495–1505.
16. HelbD, JonesM, StoryE, BoehmeC, WallaceE, et al. (2010) Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 48: 229–237.
17. TheronG, PeterJ, van Zyl-SmitR, MishraH, StreicherE, et al. (2011) Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med 184: 132–140.
18. RachowA, ZumlaA, HeinrichN, Rojas-PonceG, MtafyaB, et al. (2011) Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay—a clinical validation study. PLoS ONE 6: e20458 doi:10.1371/journal.pone.0020458.
19. Selibas K, Hanrahan C, Deery C, Dansey H, Clouse K, et al.. (2012) TB suspects with negative initial Xpert [abstract]. 3rd South African Tuberculosis Conference; 12–15 June 2012; Durban, South Africa.
20. World Health Organization (2010) Roadmap for rolling out Xpert MTB/RIF for rapid diagnosis of TB and MDR-TB. Geneva: World Health Organization.
21. World Health Organization (2012) WHO monitoring of Xpert MTB/RIF roll-out: orders of GeneXperts and Xpert MTB/RIF cartridges [database]. Available: http://www.stoptb.org/wg/gli/assets/documents/map/1/atlas.html. Accessed 4 September 2012. Geneva: World Health Organization.
22. Mirzayev F (2012) Current dynamics in the Xpert MTB/RIF assay pricing mechanisms [abstract]. Xpert MTB/RIF Early Implementers Meeting; 18–19 April 2012; Annecy, France. Geneva: World Health Organization.
23. Cepheid Pharmaceuticals (2012 Aug 6) Cepheid announces first phase of Xpert MTB/RIF buy-down for high burden developing countries. Sunnyvale (California): Cepheid Pharmaceuticals.
24. DowdyDW, CattamanchiA, SteingartKR, PaiM (2011) Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis. PLoS Med 8: e1001063 doi:10.1371/journal.pmed.1001063.
25. EvansCA (2011) GeneXpert—a game-changer for tuberculosis control? PLoS Med 8: e1001064 doi:10.1371/journal.pmed.1001064.
26. KirwanDE, CardenasMK, GilmanRH (2012) Rapid implementation of new tb diagnostic tests: is it too soon for a global roll-out of Xpert MTB/RIF? Am J Trop Med Hyg 87: 197–201.
27. LawnSD, BrooksSV, KranzerK, NicolMP, WhitelawA, et al. (2011) Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 8: e1001067 doi:10.1371/journal.pmed.1001067.
28. ScottLE, McCarthyK, GousN, NdunaM, Van RieA, et al. (2011) Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med 8: e1001061 doi:10.1371/journal.pmed.1001061.
29. TrebucqA, EnarsonDA, ChiangCY, Van DeunA, HarriesAD, et al. (2011) Xpert(R) MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how? Int J Tuberc Lung Dis 15: 1567–1572.
30. Van RieA, MelletK, JohnMA, ScottL, Page-ShippL, et al. (2012) False-positive rifampicin resistance on Xpert(R) MTB/RIF: case report and clinical implications. Int J Tuberc Lung Dis 16: 206–208.
31. RamsayA, SteingartKR, PaiM (2010) Assessing the impact of new diagnostics on tuberculosis control. Int J Tuberc Lung Dis 14: 1506–1507.
32. TheronG, PooranA, PeterJ, van Zyl-SmitR, Kumar MishraH, et al. (2012) Do adjunct tuberculosis tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting? Eur Respir J 40: 161–168.
33. World Health Organization (2011) Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and operational ‘how-to’. Geneva: World Health Organization.
34. PeltzerK, MatsekeG, MzoloT, MajajaM (2009) Determinants of knowledge of HIV status in South Africa: results from a population-based HIV survey. BMC Public Health 9: 174.
35. BaltussenR, FloydK, DyeC (2005) Cost effectiveness analysis of strategies for tuberculosis control in developing countries. BMJ 331: 1364.
36. CohenT, LipsitchM, WalenskyRP, MurrayM (2006) Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc Natl Acad Sci U S A 103: 7042–7047.
37. DowdyDW, ChaissonRE (2009) The persistence of tuberculosis in the age of DOTS: reassessing the effect of case detection. Bull World Health Organ 87: 296–304.
38. DyeC, GarnettGP, SleemanK, WilliamsBG (1998) Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet 352: 1886–1891.
39. DyeC, WilliamsBG (2000) Criteria for the control of drug-resistant tuberculosis. Proc Natl Acad Sci U S A 97: 8180–8185.
40. MurrayCJ, SalomonJA (1998) Modeling the impact of global tuberculosis control strategies. Proc Natl Acad Sci U S A 95: 13881–13886.
41. SalomonJA, Lloyd-SmithJO, GetzWM, ReschS, SanchezMS, et al. (2006) Prospects for advancing tuberculosis control efforts through novel therapies. PLoS Med 3: e273 doi:10.1371/journal.pmed.0030273.
42. DaleyCL, SmallPM, SchecterGF, SchoolnikGK, McAdamRA, et al. (1992) An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 326: 231–235.
43. ShaferRW, SinghSP, LarkinC, SmallPM (1995) Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in an immunocompetent patient. Tuber Lung Dis 76: 575–577.
44. BucherHC, GriffithLE, GuyattGH, SudreP, NaefM, et al. (1999) Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 13: 501–507.
45. ManosuthiW, TantanathipP, ChimsuntornS, EampokarapB, ThongyenS, et al. (2010) Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study. Int J Infect Dis 14: e1013–e1017.
46. van der SandeMA, Schim van der LoeffMF, BennettRC, DowlingM, AveikaAA, et al. (2004) Incidence of tuberculosis and survival after its diagnosis in patients infected with HIV-1 and HIV-2. AIDS 18: 1933–1941.
47. AdamMA, JohnsonLF (2009) Estimation of adult antiretroviral treatment coverage in South Africa. S Afr Med J 99: 661–667.
48. GranichRM, GilksCF, DyeC, De CockKM, WilliamsBG (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373: 48–57.
49. StoverJ, BollingerL, AvilaC (2011) Estimating the impact and cost of the WHO 2010 recommendations for antiretroviral therapy. AIDS Res Treat 2011: 738271.
50. UNAIDS Reference Group on Estimates, Modelling and Projections (2011) Technical meeting to review Spectrum 2011 and considering potential bias in DHS and ANC data. Geneva: Joint United Nations Programme on HIV/AIDS.
51. DowdyDW, O'BrienMA, BishaiD (2008) Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis. Int J Tuberc Lung Dis 12: 1021–1029.
52. PooleD, RafteryAE (2000) Inference for deterministic simulation models: the Bayesian melding approach. J Am Stat Assoc 95: 452.
53. RafteryAE, GivensGH, ZehJE (1995) Inference from a deterministic population dynamics model for bowhead whales. J Am Stat Assoc 90: 402–430.
54. AlkemaL, RafteryAE, BrownT (2008) Bayesian melding for estimating uncertainty in national HIV prevalence estimates. Sex Transm Infect 84: i11–i16.
55. AlkemaL, RafteryAE, ClarkSJ (2007) Probabilistic projections of HIV prevalence using Bayesian melding. Ann Appl Stat 1: 229–248.
56. BrownT, BaoL, RafteryAE, SalomonJA, BaggaleyRF, et al. (2010) Modelling HIV epidemics in the antiretroviral era: the UNAIDS Estimation and Projection package 2009. Sex Transm Infect 86 (Suppl 2)
57. World Health Organization (2011) Tuberculosis (TB) [database]. Available: http://www.who.int/tb/country/data/download/en/index.html. Accessed 30 September 2011. Geneva: World Health Organization.
58. World Health Organization (2010) Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: World Health Organization.
59. Rubin D (1988) Using the SIR algorithm to simulate posterior distributions. In: Bernardo JM, DeGroot MH, Lindley DV, Smith AFM, editors. Bayesian statistics 3. Oxford: Oxford University Press. pp. 395–402.
60. Joint United Nations Programme on HIV/AIDS (2010) Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2010. Geneva: Joint United Nations Programme on HIV/AIDS.
61. World Health Organization (2006) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach—2006 revision. Geneva: World Health Organization.
62. World Health Organization (2010) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach—2010 revision. Geneva: World Health Organization.
63. World Health Organization (2011) Global price reporting mechanism for HIV, tuberculosis and malaria. Available: http://www.who.int/hiv/amds/gprm/en/. Accessed 21 May 2011. Geneva: World Health Organization.
64. Meyer-RathG, SchnippelK, LongL, MacLeodW, SanneI, et al. (2012) The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS ONE 7: e36966 doi:10.1371/journal.pone.0036966.
65. SchnippelK, Meyer-RathG, LongL, MacleodW, SanneI, et al. (2012) Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa. Trop Med Int Health 17: 1142–1151.
66. Murray CJL, Lopez AD (1996) The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge (Massachusetts): Harvard University Press.
67. World Health Organization (2004) Global burden of disease 2004 update: disability weights for diseases and conditions. Geneva: World Health Organization.
68. Tan Torres T, Baltussen R, Adam T, Hutubessy R, Acharya A, et al.. (2003) Making choices in health: WHO guide to cost effectiveness analysis. Geneva: World Health Organization.
69. WeinsteinMC, SiegelJE, GoldMR, KamletMS, RussellLB (1996) Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276: 1253–1258.
70. HutubessyR, ChisholmD, EdejerTT (2003) Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc 1: 8.
71. ImanRL, HeltonJC, CampbellJE (1981) An approach to sensitivity analysis of computer models: part I—introduction, input variable selection and preliminary variable assessment. J Qual Technol 13: 174–183.
72. ImanRL, HeltonJC, CampbellJE (1981) An approach to sensitivity analysis of computer models: part II—ranking of input variables, response surface validation, distribution effect, and technique synopsis variable assessment. J Qual Technol 13: 232–240.
73. World Bank (2011) World development indicators 2011. Washington (District of Columbia): World Bank.
74. National Health Laboratory Service (2012) Xpert testing algorithm. South Africa: National Health Laboratory Service.
75. WilliamsBG, GranichR, De CockKM, GlaziouP, SharmaA, et al. (2010) Antiretroviral therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci U S A 107: 19485–19489.
76. Schnippel K, Rosen S, Shearer K, Martinson N, Long L, et al.. (2012) The cost of inpatient treatment for multi-drug resistant tuberculosis in South Africa [abstract]. International AIDS Economics Network 7th AIDS & Economics Pre-Conference; 22–27 July 2012; Washington, District of Columbia, US.
77. VassallA, van KampenS, SohnH, MichaelJS, JohnKR, et al. (2011) Rapid diagnosis of tuberculosis with the Xpert MTB/rif assay in high burden countries: a cost-effectiveness analysis. PLoS Med 8: e1001120 doi:10.1371/journal.pmed.1001120.
78. AndrewsJR, LawnSD, RusuC, WoodR, NoubaryF, et al. (2012) The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS 26: 987–995.
79. RachowA, ClowesP, SaathoffE, MtafyaB, MichaelE, et al. (2012) Increased and expedited case detection by Xpert MTB/RIF assay in childhood tuberculosis: a prospective cohort study. Clin Infect Dis 54: 1388–1396.
80. ZarHJ, WorkmanL, IsaacsW, MunroJ, BlackF, et al. (2012) Rapid molecular diagnosis of pulmonary tuberculosis in children using nasopharyngeal specimens. Clin Infect Dis 55: 1088–1095.
81. DyeC, WilliamsBG (2008) Eliminating human tuberculosis in the twenty-first century. J R Soc Interface 5: 653–662.
82. Frieden T (2004) Toman's tuberculosis: case detection, treatment and monitoring: questions and answers, 2nd edition. Geneva: World Health Organization.
83. LevyH, FeldmanC, SachoH, van der MeulenH, KallenbachJ, et al. (1989) A reevaluation of sputum microscopy and culture in the diagnosis of pulmonary tuberculosis. Chest 95: 1193–1197.
84. DowdyDW, ChaissonRE, MaartensG, CorbettEL, DormanSE (2008) Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc Natl Acad Sci U S A 105: 11293–11298.
85. AnglaretX, MingaA, GabillardD, OuassaT, MessouE, et al. (2012) AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire. Clin Infect Dis 54: 714–723.
86. BadriM, LawnSD, WoodR (2006) Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet 368: 1254–1259.
87. EggerM, MayM, CheneG, PhillipsAN, LedergerberB, et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360: 119–129.
88. MayM, SterneJA, SabinC, CostagliolaD, JusticeAC, et al. (2007) Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 21: 1185–1197.
89. PhillipsA, PezzottiP, CollaborationCascade (2004) Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 18: 51–58.
90. When To Start Consortium (2009) SterneJA, MayM, CostagliolaD, de WolfF, et al. (2009) Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 373: 1352–1363.
91. AlbertH (2004) Economic analysis of the diagnosis of smear-negative pulmonary tuberculosis in South Africa: incorporation of a new rapid test, FASTPlaqueTB, into the diagnostic algorithm. Int J Tuberc Lung Dis 8: 240–247.
92. FloydK, SkevaJ, NyirendaT, GausiF, SalaniponiF (2003) Cost and cost-effectiveness of increased community and primary care facility involvement in tuberculosis care in Lilongwe District, Malawi. Int J Tuberc Lung Dis 7: S29–S37.
93. HauslerHP, SinanovicE, KumaranayakeL, NaidooP, SchoemanH, et al. (2006) Costs of measures to control tuberculosis/HIV in public primary care facilities in Cape Town, South Africa. Bull World Health Organ 84: 528–536.
94. HudsonCP, WoodR, MaartensG (2000) Diagnosing HIV-associated tuberculosis: reducing costs and diagnostic delay. Int J Tuberc Lung Dis 4: 240–245.
95. NgandaB, Wang'ombeJ, FloydK, KangangiJ (2003) Cost and cost-effectiveness of increased community and primary care facility involvement in tuberculosis care in Machakos District, Kenya. Int J Tuberc Lung Dis 7: S14–S20.
96. SamandariT, BishaiD, LuteijnM, MosimaneotsileB, MotsamaiO, et al. (2011) Costs and consequences of additional chest x-ray in a tuberculosis prevention program in Botswana. Am J Respir Crit Care Med 183: 1103–1111.
97. SuarezPG, FloydK, PortocarreroJ, AlarconE, RapitiE, et al. (2002) Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 359: 1980–1989.
98. van CleeffMR, Kivihya-NduggaLE, MemeH, OdhiamboJA, KlatserPR (2005) The role and performance of chest X-ray for the diagnosis of tuberculosis: a cost-effectiveness analysis in Nairobi, Kenya. BMC Infect Dis 5: 111.
99. ReschSC, SalomonJA, MurrayM, WeinsteinMC (2006) Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med 3: e241 doi:10.1371/journal.pmed.0030241.
100. AdamT, EvansDB, MurrayCJ (2003) Econometric estimation of country-specific hospital costs. Cost Eff Resour Alloc 1: 3.
101. BikillaAD, JereneD, RobberstadB, LindtjornB (2009) Cost estimates of HIV care and treatment with and without anti-retroviral therapy at Arba Minch Hospital in southern Ethiopia. Cost Eff Resour Alloc 7: 6.
102. BrattJH, TorpeyK, KabasoM, GondweY (2011) Costs of HIV/AIDS outpatient services delivered through Zambian public health facilities. Trop Med Int Health 16: 110–118.
103. HarlingG, WoodR (2007) The evolving cost of HIV in South Africa: changes in health care cost with duration on antiretroviral therapy for public sector patients. J Acquir Immune Defic Syndr 45: 348–354.
104. MenziesNA, BerrutiAA, BerzonR, FillerS, FerrisR, et al. (2011) The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS 25: 1753–1760.
105. RosenS, LongL, SanneI (2008) The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa. Trop Med Int Health 13: 1005–1015.